arrow
G

Grzegorz Kopeć

St John Paul II Hospital
H指数:30
被引数:3,527

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The added value of echocardiography in pulmonary arterial hypertension risk assessment an artificial intelligence machine learning–derived analysis of the ULTRA RIGHT VALUE registry

超声心动图在肺动脉高压风险评估中的附加价值:一项基于人工智能机器学习的ULTRA RIGHT VALUE注册研究分析

2026-09-170
OAAI
Outcomes of catheter-directed mechanical thrombectomy in patients with cancer-associated pulmonary embolism: a multicenter, prospective registry

肿瘤相关肺栓塞患者经导管机械性血栓切除术的结局:一项多中心、前瞻性登记研究

2026-08-011
PRE
Clinically Actionable Explainable AI in Pulmonary Arterial Hypertension: Endpoints, Calibration, and External Validation. Reply to Pagnoni et al. Toward Clinically Actionable Explainable AI in Pulmonary Arterial Hypertension: Endpoints, Calibration, and External Validation. Comment on “Ledziński et al. Personalized Medicine in Pulmonary Arterial Hypertension: Utilizing Artificial Intelligence for Death Prevention. J. Clin. Med. 2025, 14, 8325”

临床可行的可解释人工智能在肺动脉高压中的应用:终点、校准与外部验证。回复Pagnoni等人。迈向临床可行的可解释人工智能在肺动脉高压中的应用:终点、校准与外部验证。评论“Ledziński等人。肺动脉高压中的个性化医学:利用人工智能预防死亡。J. Clin. Med. 2025, 14, 8325”。

2026-02-280
OAAI
The prevalence and long-term response to calcium channel blockers in patients with pulmonary arterial hypertension and positive vasoreactivity test – results of multicenter national registry (BNP-PL)

钙通道阻滞剂在肺动脉高压且血管反应性试验阳性患者中的使用普及率及长期疗效——多中心国家注册研究(BNP-PL)的结果

2026-02-250
OAAI
Safety and efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomised trial

upfront三联疗法(包括静脉注射曲前列尼尔)与双口服疗法在肺动脉高压中的安全性和有效性比较(TripleTRE研究):一项随机试验的研究方案

2026-01-190
PRE
Personalized Medicine in Pulmonary Arterial Hypertension: Utilizing Artificial Intelligence for Death Prevention

肺动脉高压中的个性化医学:利用人工智能预防死亡

2025-11-230
OAAI
Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat versus other medications: a COMPERA analysis
2025-11-031
PRE